HPV related diseases in males: a heavy vaccine-preventable burden
- PMID: 24396983
- PMCID: PMC4718386
HPV related diseases in males: a heavy vaccine-preventable burden
Abstract
Human Papillomavirus (HPV) has a significant impact in male's health, as cause of clinical manifestations ranging from genital warts to several cancers of the anogenital and aero-digestive tract. HPV types which most frequently affect men are 6, 11, 16 and 18, included in the HPV quadrivalent vaccine, recently approved for use in males by Food and Drug Administration (FDA) and European Medicines Agency (EMA). Although several data about the safety and efficacy of quadrivalent vaccine are available, the implementation of proper immunization plans dedicate to male's population cannot ignore the knowledge of the characteristics of the disease in men, which in some aspects should be clarify, in particular clearance of type-specific HPV infections and transmission dynamics. Purpose of this review is to summarise the main information about the burden and the natural history of the HPV related disease in males.
Similar articles
-
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.Lancet Infect Dis. 2022 Mar;22(3):413-425. doi: 10.1016/S1473-3099(21)00327-3. Epub 2021 Nov 12. Lancet Infect Dis. 2022. PMID: 34780705 Clinical Trial.
-
Getting to know human papillomavirus (HPV) and the HPV vaccines.J Am Osteopath Assoc. 2011 Mar;111(3 Suppl 2):S29-34. J Am Osteopath Assoc. 2011. PMID: 21415377 Review.
-
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?Euro Surveill. 2018 Oct;23(41):1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737. Euro Surveill. 2018. PMID: 30326995 Free PMC article. Review.
-
Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.BMC Cancer. 2013 Jan 8;13:10. doi: 10.1186/1471-2407-13-10. BMC Cancer. 2013. PMID: 23298365 Free PMC article.
-
Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.J Med Econ. 2023 Jan-Dec;26(1):1085-1098. doi: 10.1080/13696998.2023.2250194. J Med Econ. 2023. PMID: 37608730
Cited by
-
HPV-related diseases in male patients: an underestimated conundrum.J Endocrinol Invest. 2024 Feb;47(2):261-274. doi: 10.1007/s40618-023-02192-3. Epub 2023 Sep 28. J Endocrinol Invest. 2024. PMID: 37770654 Free PMC article. Review.
-
Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment.Hum Vaccin Immunother. 2022 Nov 30;18(6):2124091. doi: 10.1080/21645515.2022.2124091. Epub 2022 Nov 16. Hum Vaccin Immunother. 2022. PMID: 36383765 Free PMC article.
-
Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review.Vaccines (Basel). 2023 Jun 9;11(6):1083. doi: 10.3390/vaccines11061083. Vaccines (Basel). 2023. PMID: 37376472 Free PMC article. Review.
-
Impact of gender and education on cervical cancer knowledge amongst students: implications for health policies and public health strategies in Wiesbaden, Germany.J Prev Med Hyg. 2024 Aug 31;65(2):E227-E231. doi: 10.15167/2421-4248/jpmh2024.65.2.3077. eCollection 2024 Jun. J Prev Med Hyg. 2024. PMID: 39430981 Free PMC article.
-
Facilitators and barriers of healthcare workers' recommendation of HPV vaccine for adolescents in Nigeria: views through the lens of theoretical domains framework.BMC Health Serv Res. 2022 Jun 25;22(1):824. doi: 10.1186/s12913-022-08224-7. BMC Health Serv Res. 2022. PMID: 35752809 Free PMC article.
References
-
- Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2005;32(Suppl 1):S82–S90. - PubMed
-
- Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. - PubMed
-
- Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. - PubMed
-
- Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005;23:2388–2394. - PubMed
-
- Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific prevalence of anal human papillomavirus infection in HIVnegative sexually active men who have sex with men: the EXPLORE study. J Infect Dis. 2004;190:2070–2076. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials